Dallah Healthcare Reports 39% Revenue Growth in Q2, Exceeds Expectations

Dallah Healthcare Co. (DALLAH) reported a substantial increase in its second-quarter revenue, reaching 1.06 billion riyals—up 39% year-over-year and surpassing analyst expectations of 878.3 million riyals. The company's net profit grew by 11% to 124.3 million riyals, while operating profit rose nearly 10% to 155.0 million riyals, driven by expanded operational capacity and the addition of new medical facilities. Market analysts show mixed ratings: 2 buy, 6 hold, and 4 sell recommendations. The company's overall Smart Score stands at 3.4 out of 5, reflecting a positive outlook with strong momentum (score of 5) and promising growth potential (score of 4). Moderate scores in value and dividend indicate balanced valuation, while resilience suggests adaptability amid market fluctuations. Overall, Dallah Healthcare's strategic expansion and operational enhancements position it well for continued growth within Saudi Arabia's healthcare sector, indicating a favorable long-term investment outlook. Please note that this analysis is based on historical data and analyst forecasts and should not be considered financial advice. Investors should conduct independent research before making any i...